Name: Latest research reports of Aurobindo Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer

1109.9000 -7.50 (-0.67%)

NSE Sep 23, 2025 15:31 PM

27.53% Fall from 52W High

Volume: 1.4M

Aurobindo Pharma Ltd.

13 Nov 2019

1109.90

-0.67%

Aurobindo Pharma (ADD): Q2 beat; facility resolution, Sandoz key stock triggers

Buy: Aurobindo Pharma Ltd.

Target

BOB Capital Markets Ltd.

Sequential improvement in US sales to US$ 405mn and stable gross margins led to a modest beat overall in Q2.

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings